News Article | July 19, 2017
NEW YORK, July 19, 2017 (GLOBE NEWSWIRE) -- According to a new market research report “Global Scar Treatment Market Size, Share, Development, Growth and Demand Forecast to 2023 - Industry Insight by Type of Treatment (Injectable, Invasive Surgical) by Type of Scars (Post-surgical, Acne, Keloid & Hypertrophic, Contracture, Stretch Marks) and by End User (Hospital, Private Clinic, Pharmacy & Drug store and E-commerce)” published by P&S Market Research, the global scar treatment market is expected to grow at a CAGR of 10.0% during 2017 - 2023. According to the study, the global scar treatment market is likely to grow significantly during the forecast period, due to increasing prevalence of skin diseases such as psoriasis, eczema, vitiligo and photoaging of skin, which is increasing due to excessive exposure to pollution and ultraviolet radiation. This further results in sunburns, reduced skin elasticity, and hair loss. Skin diseases are also caused by various other factors, such as excessive alcohol consumption, environmental pollution, and consumption of tobacco. These conditions without proper treatment on time, can lead to the formation of scars. Various other skin problems such as, acne, burns, post-surgical marks, and stretch marks due to pregnancy or changes in body weight can also lead to scar formation. However, side effects of scar treatment products and therapies and high cost associated with scar treatment are some of the key factors restraining the growth of global scar treatment market. Geographically, North America was the largest market for scar treatment in 2016 and is expected to contribute 40.5% by 2023. This dominant position of the region is primarily attributable to high disposable income, which further increases spending on personal care products. Moreover, the increasing appearance consciousness among the population in the region has also led to a rise in the adoption of technologically advanced scar treatment products. According to the AAD, approximately 85% of the population in the U.S. suffers from acne, every year. The growing awareness about various technologies, which can enhance physical appearance of an individual is driving the demand for advanced scar treatment products in the U.S. The Asian scar treatment market is expected to grow at a faster rate as compared to the other regions, owing to growing focus on personal well-being, increasing disposable income and rising prevalence of skin related problems in the region. Key players in the scar treatment market are collaborating and acquiring other players to offer more advanced solutions for scar treatment. In March 2017, Valeant Pharmaceutical International, Inc. announced the sale of its AcneFree, AMBI and CeraVe skincare brands to L’Oréal for $1.3 billion in cash. The transaction is expected to help the company to repay term loan debt under its senior credit facility. Some of the other key players in the global scar treatment market are Smith & Nephew Plc, Syneron Medical Ltd., Mölnlycke Health Care AB, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Beijing Toplaser Technology Company Ltd., Merz GMBH & Co KGAA, Valeant Pharmaceuticals International Inc., Pacific World Corporation, Avita Medical Ltd. Enaltus LLC, Sonoma Pharmaceuticals Inc., CCA Industries Inc., Scarguard Labs LLC, Quantum Health, Hologic Inc. P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Bashaireh K.,Jordan University of Science and Technology |
Naser Z.,Private Clinic |
Hawadya K.A.,Private Clinic |
Sorour S.,Private Clinic |
Al-Khateeb R.N.,Elaf Medical Supplies Company
Drug Design, Development and Therapy | Year: 2015
Purpose: The primary objective of this study was to evaluate the efficacy, safety, and duration of action of viscosupplementation with Crespine® Gel over a 9-month period. Materials and methods: The study was a post-marketing phase IV study. A total of 109 participants with osteoarthritis of the knee (grades 1–4) in the tibio–femoral compartment were recruited in Jordan. Data were collected from each participant during the baseline visit. Each participant received Crespine® Gel injection, and follow-up visits took place at 3 months, 6 months, and 9 months post-injection. Main outcome measure(s): An assessment of participants by phone was conducted at 1 month, 2 months, 4 months, 5 months, 7 months, and 8 months post-injection. Western Ontario and McMaster Universities Arthritis Index questionnaires were completed during each visit. A 72-hour visit questionnaire was used to assess the safety of the injection. Statistical analysis included a two-sided 95% confidence interval for the difference between pain scores across visits, and the percent change from baseline was calculated. sMain results: The full analysis included 84 participants who gave their informed consent and finished the necessary baseline and follow-up visits needed to assess efficacy and safety. Peak improvement was noted at 5 months post-injection, when pain and physical performance scores had decreased to 2.60 and 9.90, respectively, and the stiffness score was 0.33. The peak improvement in stiffness was noted at 8 months post-injection, when the stiffness score had decreased to 0.32. Significant improvements were still apparent at 9 months post-injection, when the pain score was 3.36, the stiffness score was 0.42, and the physical performance score was 11.5. All side effects were local and transient, and included pain, swelling, and redness of the knee. Most side effects were treated. Conclusion: Hyaluronan should be encouraged as an alternative or adjunct treatment to oral analgesics to reduce their required doses, and delay potential future surgical intervention. © 2015 Bashaireh et al.
Addor F.A.S.,Private clinic
Anais Brasileiros de Dermatologia | Year: 2017
The skin cells continuously produce, through cellular respiration, metabolic processes or under external aggres-sions, highly reactive molecules oxidation products, generally called free radicals. These molecules are immediately neutralized by enzymatic and non-enzymatic systems in a physiological and dynamic balance. In situations where this balance is broken, various cellular structures, such as the cell membrane, nuclear or mitochondrial DNA may suffer structural modifications, triggering or worsening skin diseases. several substances with alleged antioxidant effects has been offered for topical or oral use, but little is known about their safety, possible associations and especially their mechanism of action. The management of topical and oral antioxidants can help dermatologist to intervene in the oxidative processes safely and effectively, since they know the mechanisms, limitations and potential risks of using these molecules as well as the potential benefits of available associations. © 2017 by Anais Brasileiros de Dermatologia.
Hassanian-Moghaddam H.,Shahid Beheshti University |
Farajidana H.,University of Tehran |
Sarjami S.,Private Clinic |
Owliaey H.,Shahid Beheshti University
American Journal of Emergency Medicine | Year: 2013
Background and Objectives: In contrast with other opioids, there are few cases of tramadol-related respiratory depression described in the literature, and renal impairment is a proposed risk factor. The aim of this study is to determine the prevalence of and predisposing factors for tramadol-related apnea in patients referred to our center. Patients and Methods: All patients referred to Loghman-Hakim Hospital between February 2009 and April 2010 with pure tramadol intoxication were identified retrospectively. Data collected included the patient's age, sex, ingested dose, route of exposure, reason for poisoning (acute overdose or supratherapeutic use), previous history of suicidal attempts, previous history of drug or substance abuse (including tramadol), and clinical features on admission including seizures and apnea. Results: We identified 525 patients with deliberate self-poisoning (359; 68.4%) or abuse (146; 27.8%), and in 114 (21.7%) of these, there was a history of tramadol abuse. Four hundred twenty-nine (81.7%) of patients had acute poisoning and were referred to hospital within 6 hours of ingestion. Nineteen patients (3.6%) experienced apnea and received respiratory support (16; 84.2%) or naloxone administration (3; 15.8%) within 24 hours of ingestion (mean, 7.7 ± 7 hours; range, 1-24 hours). The mean dose ingested by patients experiencing apnea was 2125 ± 1360 mg (range, 200-4600 mg), which was significantly higher than those who did not experience apnea, 1383 ± 1088 mg (range, 100-6000 mg), P <.001. One death occurred in each group, which was significant (P <.001). Renal impairment was not observed in any of the patients who experienced apnea. © 2013 Elsevier Inc. All rights reserved.
Hassanian-Moghaddam H.,Shahid Beheshti University |
Sarjami S.,Private Clinic |
Kolahi A.-A.,Shahid Beheshti University |
Carter G.L.,University of Newcastle
British Journal of Psychiatry | Year: 2011
Background: Hospital-treated self-poisoning is common, with limited effective interventions for reducing subsequent suicidal behaviour. Aims: To test the efficacy of a postcard intervention to reduce suicidal behaviour. Method: Randomised controlled trial of individuals who self-poisoned (n = 2300), the intervention consisted of nine postcards sent over 12 months versus usual treatment. Outcomes assessed at 12 months (n = 2113) were suicidal ideation, suicide attempts and self-cutting (proportion and event rates). Results: There was a significant reduction in any suicidal ideation (relative risk reduction (RRR) = 0.31, 95% CI 0.22-0.38), any suicide attempt (RRR = 0.42, 95% CI 0.11-0.63) and number of attempts (incidence rate ratios (IRR) = 0.64, 95% CI 0.42-0.97). There was no significant reduction in any self-cutting (RRR = 0.14, 95% CI -0.29 to 0.42) or self-cutting events (IRR = 1.03 95% CI 0.76-1.39). Conclusions: A postcard intervention reduced suicidal ideation and suicide attempts in a non-Western population. Sustained, brief contact by mail may reduce suicidal ideation and suicide attempts in individuals who self-poison. © 2011 The Royal College of Psychiatrists.
Addor F.A.S.,Private clinic
Anais Brasileiros de Dermatologia | Year: 2016
Recent studies about the cutaneous barrier demonstrated consistent evidence that the stratum corneum is a metabolically active structure and also has adaptive functions, may play a regulatory role in the inflammatory response with activation of keratinocytes, angiogenesis and fibroplasia, whose intensity depends primarily on the intensity the stimulus. There are few studies investigating the abnormalities of the skin barrier in rosacea, but the existing data already show that there are changes resulting from inflammation, which can generate a vicious circle caused a prolongation of flare-ups and worsening of symptoms. This article aims to gather the most relevant literature data about the characteristics and effects of the state of the skin barrier in rosacea. © 2016 by Anais Brasileiros de Dermatologia.
Bowins B.E.,Private Clinic
Counselling Psychology Quarterly | Year: 2012
Milder forms of dissociation often provide a defensive function diminishing the impact of disturbing emotional states. It is proposed that compartmentalization and absorption can be applied as psychotherapy strategies. Therapeutic compartmentalization and therapeutic absorption are easy to learn and master, and can be used to treat anxiety, depression, and other adverse emotional states. Therapeutic dissociation strategies fit in well with the real-life eclectic mix of techniques used by most psychotherapists, and can serve as an adjunct to other forms of therapy. © 2012 Copyright Taylor and Francis Group, LLC.
Handel A.C.,Private clinic |
Miot L.D.B.,São Paulo State University |
Miot H.A.,São Paulo State University
Anais Brasileiros de Dermatologia | Year: 2014
Melasma is a chronic acquired hypermelanosis of the skin, characterized by irregular brown macules symmetrically distributed on sun-exposed areas of the body, particularly on the face. It is a common cause of demand for dermatological care that affects mainly women (especially during the menacme), and more pigment-ed phenotypes (Fitzpatrick skin types III-V). Due to its frequent facial involvement, the disease has an impact on the quality of life of patients. Its pathogeny is not yet completely understood, although there are some known triggering factors such as sun exposure, pregnancy, sexual hormones, inflammatory processes of the skin, use of cosmetics, steroids, and photosensitizing drugs. There is also a clear genetic predisposition, since over 40% of patients reported having relatives affected with the disease. In this manuscript, the authors discuss the main clinical and epidemiological aspects of melasma. © 2014 by Anais Brasileiros de Dermatologia.
Zillo F.C.,Private clinic
Anais Brasileiros de Dermatologia | Year: 2014
Mycetomas are a chronic skin infection characterized by perilesional edema, formation of sinus tracts, and discharge of purulent or seropurulent exudate containing grains. This report aims to demonstrate the clinical diagnosis (by dermoscopy) of a skin lesion that initially bared no clinical features of a mycetoma. © 2014 by Anais Brasileiros de Dermatologia.
Moers-Carpi M.M.,Private Clinic |
Sherwood S.,Sally Sherwood Communications New York
Dermatologic Surgery | Year: 2013
Background In this study, we examined two polycaprolactone (PCL)-based dermal filler formulas (PCL-1; PCL-2) for safety, patient satisfaction, likelihood to return, efficacy, and duration of correction. Objective This 40-patient, 24-month, prospective, randomized, controlled study evaluated the efficacy, safety, longevity, and volume of two PCL formulas for correction of nasolabial folds. Methods Patients enrolled in a medical clinic in Europe received two injections 1 month apart and returned at 3, 6, 9, 12, 15, 18, and 24 months for blinded patient evaluation using accepted aesthetic rating scales. Results At 12 months, the efficacy outcomes on Wrinkle Severity Rating Scale (WSRS) and Global Aesthetic Improvement Scale (GAIS) of PCL-1 and PCL-2 were consistently maintained, with sustained improvement in 90% and 91.4% of patients, respectively. At 24 months, PCL-2 was found to be more effective than PCL-1 with respect to GAIS and WSRS, showing sustained improvement for the entire 2-year study period (linear p =.52; quadratic p >.99). Patient satisfaction at 24 months was 72.4% for PCL-1 and 81.7% for PCL-2. Both products were found to be safe and well tolerated. Conclusions PCL-1 and PCL-2 are safe and have sustained efficacy and high patient satisfaction, with PCL-2 demonstrating longer-lasting results than PCL-1. © 2013 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.